China Medical Device CRO & NMPA Clinical Trial Services

Cisema is a specialized Contract Research Organization (CRO) and regulatory consulting partner, supporting medical device and IVD manufacturers through the entire China clinical trial and product registration process. From study design, protocol development, and execution to regulatory submission and final National Medical Product Administration (NMPA) approval, we provide a fully integrated pathway to market success.

China has rapidly transformed from a secondary research market into a global leader in clinical development. In 2024 alone, over 4,900 clinical trials were conducted, reflecting a 13.9% year-over-year increase. With sweeping regulatory reform, increasing global data harmonization, and accelerated clinical trial approvals, China has become a strategic destination for global clinical studies, not only for pharmaceuticals, but critically for medical devices and in vitro diagnostics (IVDs).

Talk to an Expert
China Clinical Trial for Medical Devices & IVDs
700+

Combined Years of Experience

20+

Clinical Trial Sites Used

80%

Mid-Sized Manufacturer Clients

120+

Medical Device Certificates as NMPA Legal Agent

Cisema’s Clinical Trial Services for Medical Devices & IVDs

Splitting clinical trials, testing, and NMPA filings across multiple vendors creates friction, delays, and hidden costs. Cisema unifies CRO operations and regulatory management under one roof, giving you a single, accountable partner to streamline your market entry from initial strategy to final clearance.

Clinical Trial Strategy & Protocol Development

We develop a China clinical trial strategy based on your medical device, risk classification, intended use, and regulatory pathway:

Assess exemption possibilities under Chinese NMPA regulations
Design scientifically sound and NMPA-compliant protocols
Align timelines with global clinical development milestones and those of other countries.
Define primary and secondary endpoints aligned with NMPA focus areas
Optimizes sample size based on risk and feasibility

NMPA Regulatory & Ethics Committee (IEC) Submissions

We prepare and coordinate the regulatory and ethicssubmissions required to initiate your medical device clinical trial in China:

IEC applications for hospital ethics committees
Chinese-language patient-facing documents and consent forms
Timely submission within NMPA’s 60-working-day silent review system
Harmonized documentation aligned with registry and public disclosure obligations compliant with Personal Information Protection Law.

Clinical Site Selection & Principal Investigator Engagement

We identify qualified hospitals and investigators based on your medical device, study requirements, and target patient population:

Conduct feasibility assessments across leading Class 3A clinical trial hospitals in China
Connect your study with qualified Principal Investigators tailored to your therapeutic area
Manage site contracting and study agreement coordination
Provide investigator SOP training and readiness.

Clinical Trial Execution & Management

We provide local coordination and clinical trial oversight throughout study execution to maintain quality, compliance, and progress:

Fast-track enrollment from diverse patient pools, recruiting and monitoring for safety
Local support for hospital case management
Monitoring of treatment, follow-up, and patient safety, including quality control oversight during trial execution
Video updates at key stages of the process.

Clinical Data Management & Statistical Analysis

We manage and analyze clinical trial data to generatereliable, submission-ready evidence:

Develop and validate clinical trial databases
Clean clinical data and manage queries
Review and reconciles data review
Manage database lock and data archiving
Conduct statistical analysis and interpret results
Prepare clinical data and statistical reports

Trial Close-Out & NMPA Dossier Compilation

We finalize the clinical trial and prepare the documentationrequired for NMPA review and medical device registration:

Prepare the final clinical trial report in Chinese
Compile the clinical evidence summary for the medical device registration dossier
Coordinate site close-out and collect essential documents
Reconcile and archive study documentation
Compile the final medical device clinical trial documentation package

Market Access & Commercial Strategy

Following product approval, we support your transition to commercialization by guiding pricing, reimbursement, and stakeholder engagement strategies. Our market access experts help you define and communicate your product’s value within the local healthcare landscape.

Pricing and reimbursement strategy development
National Reimbursement Drug List (NRDL) pathway insights
Value proposition refinement and health economic modeling
KOL mapping, hospital access, and distribution planning
Competitor benchmarking and market positioning.

Post-Market Clinical Support & Real World Evidence

We support post-market evidence generation tomaintain compliance, monitor device performance and safety, and support futureregulatory needs:

Compliance monitoring under China’s MAH system and APAC-specific requirements.
Medical Device & IVD PMS report generation, PSURs, and signal detection
Phase IV and post-market clinical follow-up (PMCF) planning
Real world evidence (RWE) study design and implementation

Why MedTech Leaders Partner with Cisema for China Medical Device Clinical Trials

As a specialist Contract Research Organization (CRO) and regulatory partner, Cisema guides medical device and IVD manufacturers through every stage of China clinical trials and NMPA registration, from study design to final approval. By aligning clinical and NMPA regulatory requirements from the outset, we streamline the process, eliminates costly handovers, and serve as your single-source partner for a clear, cost-transparent route to the Chinese market.

1

Built for International Sponsors

We understand global quality standards, Western documentation, and multinational decision-making, eliminating the misunderstandings and delays typical of domestic-focused CROs.

2

Flexible, Tailored Delivery

Rather than forcing your study into a standardized CRO model, we keep senior leadership close to delivery and tailor teams and workflows to your medical device and registration goals.

3

Coordinated Trial Execution

We align sponsors, regulatory teams, hospitals, investigators, and service providers from day one, resolving bottlenecks early and keeping key decisions on track.

4

Dual Project Management

We pair a sponsor-facing lead focused on strategy and budgets with a dedicated clinical trial manager driving daily execution in China, bridging headquarters with on-the-ground reality.

Our 5-Step Process for China Medical Device Trial Success

Step 1: Build a Dedicated Project Team

Create a customized Clinical Trial Project Development (CTPD) plan to optimize costs, timelines, and overall project efficiency.

Step 2: Build a Dedicated Project Team

Establish a professional team comprising a Project Supervisor, client-side Project Manager, site Project Manager, CRA, and medical experts.

Step 3: Build a Dedicated Project Team

Hold regular meetings between Cisema’s team and the client’s team to maintain alignment and address project issues promptly.

Step 4: Conduct a Protocol Discussion Panel

Organize a Protocol Discussion Panel involving the Principal Investigator (PI) and client to review and align on the clinical trial protocol.

Step 5: Support the NMPA Review Process

Manage clinical data collection and report preparation while supporting the client throughout the NMPA technical review and supplementary process.

China Medical Device CRO FAQs

Not necessarily. Devices on the NMPA Exemption Catalogue or supported by sufficient existing clinical evaluation may bypass local clinical trials. Cisema can assess your product and evidence to identify the leanest pathway.

Yes, provided it meets NMPA’s overseas clinical data acceptance guidelines. We evaluate your global dataset for ethnic differences and GCP compliance to determine if supplemental local data is needed.

CROs with an on the ground presence in China and global perspective provide the regulatory knowledge, hospital and investigator network, and on-the-ground coordination needed to manage China-specific clinical trial requirements. Cisema combines these capabilities with international regulatory expertise.

Yes. We match your medical device with suitable hospitals and investigators based on your study requirements, and target patient population. We can also coordinate site start-up, contracting, training, and ongoing communication throughout the clinical trial.

Timelines vary based on enrollment targets, site count, and ethics board approvals. Cisema can assess your project and identify key milestones, dependencies, and potential timeline risks before the study begins.

Pricing depends on trial scope, site volume, patient cohort size, and data management needs. We provide transparent, itemized proposals tailored to your project milestones.

Why Global Sponsors Choose China for Medical Device & IVD Clinical Trials

Unprecedented Scale and Opportunity

  • 4,900+ clinical trials conducted in 2024, including pharmaceutical trials
  • 51.8% of trials focused on innovative products
  • Large, treatment-naive patient populations
  • Growth in multinational and global clinical trials
  • Extensive hospital network, including Class III Grade A hospitals in major cities, providing a competitive landscape for clinical research

Regulatory Transformation Under the NMPA

  • 60-working-day silent approval mechanism for clinical trial applications
  • Proposed 30-day review timeline for priority products
  • Shift from site accreditation to site registration
  • Greater alignment with ICH standards for global data acceptance

Cost and Speed Advantages

  • Lower costs compared with many other markets
  • Expanding CRO ecosystem providing full-service support
  • Backed by the Chinese government through policies promoting Innovation, quality control and new guidance to streamline the clinical trial process.

Discuss Your China Medical Device Clinical Trial

Cisema’s clinical trial and regulatory specialists are ready to guide your medical device or IVD through every step in China. Let us help you design, execute, and submit a successful clinical trial that meets NMPA requirements, ensures data accuracy, and accelerates your product’s market entry.

Talk to an Expert

Latest Regulatory News

View More

China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices

China has introduced GMP inspection guidelines for sterile, implantable, IVD, custom-made denture and standalone software medical devices.

November 16, 2026
China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices
Two Chinese laboratory professionals check a benchtop blood analyzer as one loads a rack of capped sample tubes.

India Clarifies How Medical Device Software, and AI-Enabled Tools Are Regulated

India’s CDSCO releases final medical device software guidance under MDR 2017, outlining licensing routes, software risk classes, and cybersecurity standards.

November 16, 2026
India Clarifies How Medical Device Software, and AI-Enabled Tools Are Regulated
Two Indian clinicians review a chest X-ray on a tablet, where diagnostic software has flagged an area in one lung.

Singapore Updates GN-15 Medical Device Registration Guidance

Singapore’s HSA has revised GN-15 medical device registration guidance, updating submission templates, SaMD requirements and post-market expectations.

November 12, 2026
Singapore Updates GN-15 Medical Device Registration Guidance

Indonesia Extends Mandatory Halal Certification Deadlines

Indonesia extends halal certification deadlines for medicines, medical devices, cosmetics, and other regulated products, giving additional time to meet compliance requirements.

November 3, 2026
Indonesia Extends Mandatory Halal Certification Deadlines

China Issues Battery Registration Guidance for Active Implantable Medical Devices

See how China’s new battery registration guidance affects technical documentation, supplier coordination, and NMPA review of active implantable medical devices.

November 2, 2026
China Issues Battery Registration Guidance for Active Implantable Medical Devices

China Issues Clinical Trial Guidance for Implantable Brain-Computer Interface Systems

China's CMDE guidance defines clinical trial and registration considerations for implantable BCI devices, including patient selection, endpoints, and post-market follow-up.

November 2, 2026
China Issues Clinical Trial Guidance for Implantable Brain-Computer Interface Systems
Previous
Previous